Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Middle East Contract Win

26 Aug 2014 07:00

RNS Number : 8994P
MyCelx Technologies Corporation
26 August 2014
 



Not for release, publication or distribution directly or indirectly, in whole or in part, in or into or from the United States of America (including its territories and possessions, any state of the United States, and the District of Columbia), Canada, Australia, the Republic of South Africa, the Republic of Ireland or Japan, or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

This press release does not constitute or form a part of, and should not be construed as, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities in MYCELX Technologies Corporation ("MYCELX" or the "Company").

THE COMPANY'S COMMON SHARES HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT") OR ANY STATE SECURITIES LAWS (THE "STATE ACTS") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS THE SECURITIES ARE REGISTERED UNDER THE US SECURITIES ACT AND ANY APPLICABLE STATE ACTS, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE US SECURITIES ACT AND ANY APPLICABLE STATE ACTS IS AVAILABLE.

 

 

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

26 August 2014

Middle East Contract Win

 

MYCELX Technologies Corporation (AIM: MYX), the clean water technology company providing patented solutions for commercial industrial markets worldwide, is pleased to announce a new contract win in the Middle East.

 

The Company has been awarded a water treatment contract from a Kuwaiti petrochemical company for a project that will take place in Q4 2014. This follows the Company's successful market entry into Kuwait earlier this year, the installation of one of the Company's systems and an initial six month contract with the same petrochemical company.

 

Whilst the Company's focus is on securing long term contracts with all the benefits of recurring revenue generation, this win demonstrates how the MYCELX systems are designed to manage difficult and fluctuating influent conditions and volume, and is therefore ideally suited for turnaround projects and emergency response given the reliability, mobility and small physical footprint.

 

Connie Mixon, CEO of MYCELX, commented:

 

"The Middle East region remains an area of specific opportunity for MYCELX and we are delighted to build upon our market entry into Kuwait earlier this year with this new contract award. We faced tough competition to secure this contract, which is further evidence that our technology and treatment systems offer leading edge performance in extremely challenging conditions.

 

The nature of this contract will generate significant revenue most of which will be recognised in this year and is a demonstration of how our investment in personnel and infrastructure for new business development in the region continues to yield significant dividends. "

 

 

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Mark Clark, CFO Tel: +1 888 306 6843

 

Numis Securities Limited

Corporate Finance

Stuart Skinner / Jamie Loughborough

 

Corporate Broking

James Black / Ben Stoop Tel: +44 20 7260 1000

 

Bell Pottinger

Mark Antelme / Nick Lambert / Henry Lerwill Tel: +44 20 7861 3232

 

 

Notes for Editors

 

· MYCELX Technologies Corporation is a clean water technology company that provides novel water treatment solutions to the oil and gas, power, marine and manufacturing sectors

 

· MYCELX invented and is the owner of the MYCELX polymer which is infused in the consumable media contained in equipment supplied by the Company

 

· The technology produces treatment results that compare favourably to existing competition in effectiveness, cost and footprint. The MYCELX polymer and its use are protected by patents and other intellectual property rights

 

· The defining difference of the MYCELX polymer as compared with alternative technologies currently available is that it is capable of permanently and reliably removing free, emulsified and dissolved hydrocarbons from water upon contact to levels between 0-10 parts per million (ppm) at any flow rate

 

· MYCELX equipment has been installed successfully at the facilities of leading industry operators around the globe. The focus of the Company is now directed at the commercial application of MYCELX solutions in both upstream and downstream markets in the oil and gas industry

 

· Over the last three years, the Company has sold its products primarily in the Middle East, North America, Asia, Australia, and Europe. Customers include global oil and gas and petrochemical companies such as Chevron, BP, SABIC, Anadarko Petroleum, engineering, procurement and construction companies and global water treatment companies

 

· Further information on MYCELX Technologies Corporation can be found at www.MYCELX.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTQKBDKNBKBCFB
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.